Production (Stage)
Aquestive Therapeutics, Inc.
AQST
$2.35
$0.062.62%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Net Income | -78.75% | -110.27% | -465.55% | 52.61% | -259.00% |
Total Depreciation and Amortization | -32.85% | -65.59% | -39.77% | -29.07% | -36.31% |
Total Amortization of Deferred Charges | 2.88% | 50.11% | 4,430.51% | 4,423.73% | 4,673.21% |
Total Other Non-Cash Items | 1.30% | 22.05% | 103.12% | 96.47% | 1,819.05% |
Change in Net Operating Assets | -143.75% | 580.36% | -236.26% | -170.85% | -823.67% |
Cash from Operations | -125.35% | -31.30% | -406.18% | 11.39% | -217.79% |
Capital Expenditure | -365.52% | 6.25% | 47.02% | 95.76% | -1,350.00% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -365.52% | 6.25% | 47.02% | 95.76% | -1,350.00% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -20.00% | 99.99% | -60.00% | 99.86% | 99.94% |
Issuance of Common Stock | -74.15% | -95.35% | -96.13% | -77.78% | 8,921.72% |
Repurchase of Common Stock | 21.28% | -- | -- | -66.67% | -11,062.50% |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -100.06% | -- | -- | -- |
Cash from Financing | -74.74% | -95.99% | -100.34% | -60.09% | 988.01% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -104.05% | -507.37% | -582.75% | -19.88% | 18,342.46% |